{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T10:40:18Z","timestamp":1790505618726,"version":"4.1.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,1,15]],"date-time":"2019-01-15T00:00:00Z","timestamp":1547510400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Respir Res"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s12931-019-0974-5","type":"journal-article","created":{"date-parts":[[2019,1,15]],"date-time":"2019-01-15T08:02:52Z","timestamp":1547539372000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":52,"title":["Absence of early metabolic response assessed by 18F-FDG PET\/CT after initiation of antifibrotic drugs in IPF patients"],"prefix":"10.1186","volume":"20","author":[{"given":"Benjamin","family":"Bondue","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Am\u00e9lie","family":"Castiaux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaetan","family":"Van Simaeys","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9line","family":"Mathey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F\u00e9licie","family":"Sherer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"Egrise","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Lacroix","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Huaux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilles","family":"Doumont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serge","family":"Goldman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,1,15]]},"reference":[{"issue":"6","key":"974_CR1","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1164\/rccm.2009-040GL","volume":"183","author":"G Raghu","year":"2011","unstructured":"Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, et al. An official ATS\/ERS\/JRS\/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011;183(6):788\u2013824.","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"974_CR2","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1164\/ajrccm.157.1.9704130","volume":"157","author":"JA Bjoraker","year":"1998","unstructured":"Bjoraker JA, Ryu JH, Edwin MK, Myers JL, Tazelaar HD, Schroeder DR, Offord KP. Prognostic significance of histopathologic subsets in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 1998;157(1):199\u2013203.","journal-title":"Am J Respir Crit Care Med"},{"issue":"8","key":"974_CR3","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1586\/1744666X.2014.917050","volume":"10","author":"P Spagnolo","year":"2014","unstructured":"Spagnolo P, Rossi G, Cavazza A. Pathogenesis of idiopathic pulmonary fibrosis and its clinical implications. Expert Rev Clin Immunol. 2014;10(8):1005\u201317.","journal-title":"Expert Rev Clin Immunol"},{"issue":"4","key":"974_CR4","first-page":"538","volume":"50","author":"AM Groves","year":"2009","unstructured":"Groves AM, Win T, Screaton NJ, Berovic M, Endozo R, Booth H, et al. Idiopathic pulmonary fibrosis and diffuse parenchymal lung disease: implications from initial experience with 18F-FDG PET\/CT. J Nucl Med Off Publ Soc Nucl Med. 2009;50(4):538\u201345.","journal-title":"J Nucl Med Off Publ Soc Nucl Med"},{"issue":"2","key":"974_CR5","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1007\/s00259-013-2514-8","volume":"41","author":"T Win","year":"2014","unstructured":"Win T, Thomas BA, Lambrou T, Hutton BF, Screaton NJ, Porter JC, et al. Areas of normal pulmonary parenchyma on HRCT exhibit increased FDG PET signal in IPF patients. Eur J Nucl Med Mol Imaging. 2014;41(2):337\u201342.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"5","key":"974_CR6","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1007\/s00259-017-3917-8","volume":"45","author":"T Win","year":"2018","unstructured":"Win T, Screaton NJ, Porter JC, Ganeshan B, Maher TM, Fraioli F, et al. Pulmonary 18F-FDG uptake helps refine current risk stratification in idiopathic pulmonary fibrosis (IPF). Eur J Nucl Med Mol Imaging. 2018;45(5):806\u201315.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"6","key":"974_CR7","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1097\/MNM.0000000000000083","volume":"35","author":"EYP Lee","year":"2014","unstructured":"Lee EYP, Wong CS, Fung SL, Yan PK, Ho JCM. SUV as an adjunct in evaluating disease activity in idiopathic pulmonary fibrosis - a pilot study. Nucl Med Commun. 2014;35(6):631\u20137.","journal-title":"Nucl Med Commun"},{"issue":"1","key":"974_CR8","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s12931-017-0556-3","volume":"18","author":"A Justet","year":"2017","unstructured":"Justet A, Laurent-Bellue A, Thabut G, Dieudonn\u00e9 A, Debray M-P, Borie R, et al. [(18)F]FDG PET\/CT predicts progression-free survival in patients with idiopathic pulmonary fibrosis. Respir Res. 2017;18(1):74.","journal-title":"Respir Res"},{"issue":"12","key":"974_CR9","first-page":"1899","volume":"57","author":"T Nobashi","year":"2016","unstructured":"Nobashi T, Kubo T, Nakamoto Y, Handa T, Koyasu S, Ishimori T, et al. 18F-FDG uptake in less affected lung field provides prognostic stratification in patients with interstitial lung disease. J Nucl Med Off Publ Soc Nucl Med. 2016;57(12):1899\u2013904.","journal-title":"J Nucl Med Off Publ Soc Nucl Med"},{"issue":"12","key":"974_CR10","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.1164\/rccm.201504-0780OC","volume":"192","author":"N Xie","year":"2015","unstructured":"Xie N, Tan Z, Banerjee S, Cui H, Ge J, Liu R-M, et al. Glycolytic reprogramming in myofibroblast differentiation and lung fibrosis. Am J Respir Crit Care Med. 2015;192(12):1462\u201374.","journal-title":"Am J Respir Crit Care Med"},{"issue":"12","key":"974_CR11","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1164\/rccm.201508-1699ED","volume":"192","author":"TM Maher","year":"2015","unstructured":"Maher TM. Aerobic glycolysis and the Warburg effect. An unexplored realm in the search for fibrosis therapies? Am J Respir Crit Care Med. 2015;192(12):1407\u20139.","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"974_CR12","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1165\/rcmb.2016-0225OC","volume":"56","author":"SJ Cho","year":"2017","unstructured":"Cho SJ, Moon J-S, Lee C-M, Choi AM, Stout-Delgado HW. Glucose transporter 1-dependent glycolysis is increased during aging-related lung fibrosis, and Phloretin inhibits lung fibrosis. Am J Respir Cell Mol Biol. 2017;56(4):521\u201331.","journal-title":"Am J Respir Cell Mol Biol"},{"issue":"1","key":"974_CR13","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1046\/j.1365-201X.2002.00970.x","volume":"175","author":"K Mamchaoui","year":"2002","unstructured":"Mamchaoui K, Makhloufi Y, Saumon G. Glucose transporter gene expression in freshly isolated and cultured rat pneumocytes. Acta Physiol Scand. 2002;175(1):19\u201324.","journal-title":"Acta Physiol Scand"},{"issue":"4","key":"974_CR14","first-page":"278","volume":"47","author":"K Isobe","year":"2009","unstructured":"Isobe K, Hata Y, Sugino K, Takai Y, Shibuya K, Homma S. Usefulness of FDG-PET for diagnosis of lung cancer associated with interstitial pneumonia. Nihon Koky\u016bki Gakkai Zasshi J Jpn Respir Soc. 2009;47(4):278\u201385.","journal-title":"Nihon Koky\u016bki Gakkai Zasshi J Jpn Respir Soc"},{"issue":"1","key":"974_CR15","first-page":"127","volume":"56","author":"B Bondue","year":"2015","unstructured":"Bondue B, Sherer F, Van Simaeys G, Doumont G, Egrise D, Yakoub Y, et al. PET\/CT with 18F-FDG- and 18F-FBEM-labeled leukocytes for metabolic activity and leukocyte recruitment monitoring in a mouse model of pulmonary fibrosis. J Nucl Med Off Publ Soc Nucl Med. 2015;56(1):127\u201332.","journal-title":"J Nucl Med Off Publ Soc Nucl Med"},{"key":"974_CR16","unstructured":"European Medicines Agency. Summary of Product Characteristics - Esbriet (pirfenidone). 2018. \n                    http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/human\/medicines\/002154\/human_med_001417.jsp&mid=WC0b01ac058001d124\n                    \n                   (Accessed April 24 2018)."},{"key":"974_CR17","unstructured":"European Medicines Agency. Summary of Product Characteristics - Ofev (nintedanib). 2017.\n                    http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_Product_Information\/human\/003821\/WC500182474.pdf\n                    \n                   (Accessed March 27 2018)."},{"issue":"12","key":"974_CR18","doi-asserted-by":"publisher","first-page":"2238","DOI":"10.1007\/s00259-011-1906-x","volume":"38","author":"T Lambrou","year":"2011","unstructured":"Lambrou T, Groves AM, Erlandsson K, Screaton N, Endozo R, Win T, et al. The importance of correction for tissue fraction effects in lung PET: preliminary findings. Eur J Nucl Med Mol Imaging. 2011;38(12):2238\u201346.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"18","key":"974_CR19","doi-asserted-by":"publisher","first-page":"7387","DOI":"10.1088\/0031-9155\/60\/18\/7387","volume":"60","author":"BF Holman","year":"2015","unstructured":"Holman BF, Cuplov V, Millner L, Hutton BF, Maher TM, Groves AM, et al. Improved correction for the tissue fraction effect in lung PET\/CT imaging. Phys Med Biol. 2015;60(18):7387\u2013402.","journal-title":"Phys Med Biol"},{"issue":"6","key":"974_CR20","first-page":"999","volume":"47","author":"BJ Fueger","year":"2006","unstructured":"Fueger BJ, Czernin J, Hildebrandt I, Tran C, Halpern BS, Stout D, et al. Impact of animal handling on the results of 18F-FDG PET studies in mice. J Nucl Med. 2006;47(6):999\u20131006.","journal-title":"J Nucl Med"},{"issue":"3","key":"974_CR21","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1164\/rccm.201604-0801CI","volume":"194","author":"HR Collard","year":"2016","unstructured":"Collard HR, Ryerson CJ, Corte TJ, Jenkins G, Kondoh Y, Lederer DJ, et al. Acute exacerbation of idiopathic pulmonary fibrosis. An international working group report. Am J Respir Crit Care Med. 2016;194(3):265\u201375.","journal-title":"Am J Respir Crit Care Med"},{"issue":"10","key":"974_CR22","doi-asserted-by":"publisher","first-page":"684","DOI":"10.7326\/0003-4819-156-10-201205150-00004","volume":"156","author":"B Ley","year":"2012","unstructured":"Ley B, Ryerson CJ, Vittinghoff E, Ryu JH, Tomassetti S, Lee JS, et al. A multidimensional index and staging system for idiopathic pulmonary fibrosis. Ann Intern Med. 2012;156(10):684\u201391.","journal-title":"Ann Intern Med"},{"issue":"5","key":"974_CR23","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1023\/A:1007068313370","volume":"24","author":"SN Iyer","year":"2000","unstructured":"Iyer SN, Hyde DM, Giri SN. Anti-inflammatory effect of pirfenidone in the bleomycin-hamster model of lung inflammation. Inflammation. 2000;24(5):477\u201391.","journal-title":"Inflammation"},{"key":"974_CR24","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/1465-9921-15-16","volume":"15","author":"M Inomata","year":"2014","unstructured":"Inomata M, Kamio K, Azuma A, Matsuda K, Kokuho N, Miura Y, et al. Pirfenidone inhibits fibrocyte accumulation in the lungs in bleomycin-induced murine pulmonary fibrosis. Respir Res. 2014;15:16.","journal-title":"Respir Res"},{"issue":"3","key":"974_CR25","first-page":"1800","volume":"16","author":"X Song","year":"2018","unstructured":"Song X, Yu W, Guo F. Pirfenidone suppresses bleomycin-induced pulmonary fibrosis and periostin expression in rats. Exp Ther Med. 2018;16(3):1800\u20136.","journal-title":"Exp Ther Med"},{"issue":"1\u20133","key":"974_CR26","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/j.ejphar.2008.06.046","volume":"590","author":"H Oku","year":"2008","unstructured":"Oku H, Shimizu T, Kawabata T, Nagira M, Hikita I, Ueyama A, Matsushima S, Torii M, Arimura A. Antifibrotic action of pirfenidone and prednisolone: different effects on pulmonary cytokines and growth factors in bleomycin-induced murine pulmonary fibrosis. Eur J Pharmacol. 2008;590(1\u20133):400\u20138.","journal-title":"Eur J Pharmacol"},{"key":"974_CR27","doi-asserted-by":"publisher","unstructured":"Ronan N, Bennett DM, Khan KA, McCarthy Y, Dahly D, Bourke L, Chelliah A, Cavazza A, O'Regan K, Moloney F, Plant BJ, Henry MT. Tissue and Bronchoalveolar lavage biomarkers in idiopathic pulmonary fibrosis patients on Pirfenidone. Lung. 2018. \n                    https:\/\/doi.org\/10.1007\/s00408-018-0140-8\n                    \n                  .","DOI":"10.1007\/s00408-018-0140-8"},{"issue":"1","key":"974_CR28","doi-asserted-by":"publisher","first-page":"e000325","DOI":"10.1136\/bmjresp-2018-000325","volume":"5","author":"TM Maher","year":"2018","unstructured":"Maher TM, Stowasser S, Nishioka Y, White ES, Cottin V, Noth I, et al. Investigating the effects of nintedanib on biomarkers of extracellular matrix turnover in patients with IPF: design of the randomised placebo-controlled INMARK\u00aetrial. BMJ Open Respir Res. 2018;5(1):e000325.","journal-title":"BMJ Open Respir Res"}],"container-title":["Respiratory Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12931-019-0974-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12931-019-0974-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12931-019-0974-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,3]],"date-time":"2020-02-03T09:17:14Z","timestamp":1580721434000},"score":1,"resource":{"primary":{"URL":"https:\/\/respiratory-research.biomedcentral.com\/articles\/10.1186\/s12931-019-0974-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,15]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["974"],"URL":"https:\/\/doi.org\/10.1186\/s12931-019-0974-5","relation":{},"ISSN":["1465-993X"],"issn-type":[{"value":"1465-993X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,15]]},"assertion":[{"value":"5 October 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 January 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 January 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Experiments in mice were approved by the local committee for animal welfare (CMMI).For the human study, the protocol has been approved by the Erasme hospital Ethics Committee (ref. P2016\/427). Written informed consent for participation in the study was obtained from all the patients.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"B.B. received grants, consultancies and lecture fees from La Roche-Hoffmann and Boehringer Ingelheim. Other authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"10"}}